Equine degenerative myeloencephalopathy: prevalence, impact, and management

Erin N Burns
Carrie J Finno
Department of Population Health and Reproduction, School of Veterinary Medicine, University of California-Davis, Davis, CA, USA

Abstract: Equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy is an inherited neurodegenerative disorder affecting many horse breeds. Clinical signs include a symmetric ataxia and an abnormal stance at rest, similar to cervical vertebral compressive myelopathy, equine protozoal myeloencephalitis, and equine herpesvirus 1 myeloencephalopathy. This review will provide an update on the disease prevalence, management, impact, and ongoing research.

Keywords: ataxia, α-tocopherol, horse, vitamin E, gestation, foal, pasture

Introduction

Equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy (eNAD/EDM) is an inherited neurodegenerative disease characterized by the development of ataxia within the first year of life. Histologic hallmarks of eNAD/EDM include spheroids, axonal loss, and secondary demyelination within the caudal brainstem and spinal cord. eNAD and EDM are clinically indistinguishable, with EDM being a more advanced form of the disease. The histologic lesions in eNAD are confined to the cuneate and gracile nuclei of the caudal medulla oblongata, while in EDM, the lesions are more widespread and include demyelination within the ascending tracts of the spinal cord. Immunohistochemical calretinin staining has defined afferent proprioceptive tracts as the primary tracts damaged in eNAD/EDM horses, and isolated soma within the dorsal root ganglia as the source of dystrophic axons.

While a genetic susceptibility to eNAD/EDM is highly suspected, the genetic basis of eNAD/EDM currently remains unknown. Previous studies in Quarter Horses, Appaloosas, Morgans, and Standardbreds indicated an autosomal dominant and incompletely penetrant mode of inheritance. The disease has been reported in multiple breeds and a breed-specific susceptibility has not been identified.

The clinical signs of eNAD/EDM are an early onset of symmetric ataxia (≥ grade 2/5), abnormal stance at rest, prominent hypermetria when walked with the head elevated, and general proprioceptive deficits. Some reports also detail additional neurologic symptoms including a decreased or absent menace response, lack of fight or flight response, and increased severity of ataxia in the pelvic limbs. Decreased serum α-tocopherol levels within the first 4 months of life have also been reported in some eNAD/EDM cases. In rare cases, eNAD/EDM has been reported concurrently with equine motor neuron disease.

There are other neurological diseases which are clinically indistinguishable from eNAD/EDM. For example, horses affected with cervical vertebral compressive...
myelopathy (CVCM), equine protozoal myeloencephalitis (EPM), or equine herpesvirus-1 myeloencephalopathy (EHM) demonstrate similar clinical signs as individuals with eNAD/EDM. EPM can be confirmed through antibody detection tests of cerebrospinal fluid and serum. EHM can be confirmed through virus culture of EHV-1 and molecular testing. A likely diagnosis of CVCM can be excluded based on standing cervical radiographs, myelography, or computed tomography. Cytological evaluation of cerebrospinal fluid does not typically reveal any abnormalities with CVCM or eNAD/EDM. Currently, the only way to definitively diagnose eNAD/EDM and CVCM is through postmortem histologic evaluation of the brainstem and spinal cord.

**Vitamin E**

Early studies of eNAD/EDM determined that foals raised on pasture incurred a protective effect against the development of the disease. It was hypothesized that this protective effect was due to the increased consumption of vitamin E (vitE) as grazing pasture has a range of 45–400 IU vitE/kg of dry matter. This hypothesis was also supported in vitE supplementation studies, demonstrating a decrease in disease incidence within susceptible populations when supplemented. The average 500 kg horse living on pasture would consume between 350 and 3,000 IU of vitE/d when consuming 1.7% of their body weight in a 90% dry matter diet. This range is variable because the vitE available on pasture is subject to change based on the forage type available and the time of year. Serum α-tocopherol concentrations have been shown to fluctuate seasonally, with the highest concentrations identified between June and August, and the lowest between February and May.

There are many different products on the market to supplement vitE into a horse’s diet. RRR-α-tocopherol (α-tocopherol) is the most bioactive isomer of vitE. All racemic vitE contains 2 different isomers of vitE (d-α-tocopherol and L-α-tocopherol). It is not recommended to supplement with all racemic vitE or synthetic vitE at any dose as it is not bioavailable. When supplementing with RRR-α-tocopherol, also called natural vitE, 10 IU/kg/d should be administered for a suspect eNAD/EDM-affected horse.

Based on the authors’ clinical observations of eNAD/EDM, we recommend 10 IU/kg/d of water-soluble natural vitE (RRR-α-tocopherol), totaling 5,000 IU/d for the average adult horse. This water-soluble natural vitE is absorbed rapidly and therefore increases serum concentrations most efficiently. The mechanism by which vitE protects a foal from disease development is currently not fully understood. It is known that RRR-α-tocopherol (α-tocopherol) is the most potent, bioavailable isoform of vitE, and that oxidative stress is occurring in the brainstem and spinal cord of eNAD/EDM-affected horses. Current research is ongoing to determine the exact cause of this oxidative injury and how vitE prevents such damage.

**Prevalence**

There are many breeds affected by eNAD/EDM including the Standardbred, Appaloosa, Morgan, Lusitano, Paint, Thoroughbred, Arabian, Norwegian Fjord, and Quarter Horse. As a definitive diagnosis of eNAD/EDM requires postmortem evaluation of the central nervous system, prevalence of the disease would more accurately be assessed with a genetic marker or biochemical assay. When diagnosing eNAD/EDM antemortem, it is imperative that the veterinarian rule out all other possible causes of the observed neurological deficits (CVCM, EPM, EHM, and trauma). Alpha-Tocopherol supplementation may be indicated if the serum α-tocopherol levels are <2 µg/mL, and a history of neurological disease exists in related individuals.

A prospective study at Cornell University College of Veterinary Medicine found that EDM (n=23) was the second leading cause of equine spinal cord disease among all necropsied spinal cord disease cases between 1974 and 1976. In this population of horses, EPM (n=32) was the leading cause of neurologic disease, with a total of 96 horses evaluated. Eleven years later, a retrospective study of 19 ataxic horses was published by the University of Montreal College of Veterinary Medicine. In this study, CVCM was the leading cause of ataxia (n=11), and EDM was the second leading cause (n=4). In evaluating both these studies based on postmortem confirmed diagnoses of spinal ataxia, it can be concluded that CVCM, EPM, and eNAD/EDM account for the majority of spinal ataxia presentations in horses.

Since many neurologic horses are euthanized without postmortem evaluation, it is impossible to know the true prevalence of eNAD/EDM. The study of this disease is also complicated by the environments foals are raised in. If a susceptible foal is raised on pasture, they are less likely to demonstrate clinical signs of the disease, thus masking individuals who would have underlying predisposition for the disease. A 1990 study also found that application of insecticide, exposure to wood preservatives, and frequent time spent on dirt lots were risk factors for eNAD/EDM.
Later epidemiological studies were able to confirm the risk associated with low vitE levels (ie, frequent time spent in dirt lots without access to pasture) but not the other factors.34 Case reports have demonstrated that eNAD/EDM affects horses globally. Equine NAD/EDM has been diagnosed in horses residing in New York,5,13,20 California,16 Nebraska,31 Iowa,4 the United Kingdom,26 Italy,28 and Spain.25 Researchers have also studied eNAD/EDM in Iowa,4 Minnesota,3 California,17,24,32 Oregon,6,11 and Florida.5 With this geographic distribution, we do not suspect there to be a specific geographic region in which eNAD/EDM cases are confined to, but for the number of cases to be increased in area where access to pasture is limited.

Impact
Any ataxic horse is not suitable for any riding purpose. Because eNAD/EDM is an inherited disorder, these individuals are also not suited for breeding. This causes an economic loss to the equine breeding and training industries.

The economic impact on the training and breeding industry can be estimated by the amount of money invested in the production of an affected horse. Although clinical cases may present between 2 and 3 years of age,1 the disease typically develops within the first year of life.16,20 The authors suspect this discrepancy to be caused by the increased workload, allowing owners and trainers to observe the lack of coordination that has existed since early in the animals’ life. As young horses enter a training regimen, they are continually asked to perform at increasingly higher levels. Affected horses would be unable to meet these expectations, and subsequently be examined by a veterinarian for possible causes.

Long-term supplementation with 10 IU/kg/d is a financial burden on the breeding and training industry that must be considered when making breeding management decisions. The cost of supplementation for 1 genetically susceptible foal over the course of 2 years is nearly $3,500 (Table 1). Both the mare and the foal must be supplemented with this high dose of D-α-tocopherol (RRR-α-tocopherol) to achieve sufficient protective effects. As the current methods to deliver water-soluble D-α-tocopherol (RRR-α-tocopherol) require daily oral administration of the most bioavailable liquid supplement, the burden of time spent dosing several horses within a breeding or training program can be substantial.

Management
Once clinical signs of ataxia are apparent, α-tocopherol supplementation will not improve the neurologic deficits. Progression of the disease can be halted through supplementation, but the general proprioceptive ataxia will remain. Clinical signs of the disease typically progress at varying rates until the horse reaches 2 years of age, at which time signs stabilize.

Currently the best management practice for prevention of eNAD/EDM is to maintain pregnant mares, foals, weanlings, yearlings, and 2-year-old horses on lush green pastures. This ensures adequate consumption of vitE to protect against neurodegeneration in the developing central nervous system. If

| Table 1 Average cost of D-α-tocopherol (RRR-α-tocopherol) supplementation per affected foal |
|-----------------------------------------------|---------------|-----------|-------------|-------------|-------------|
| Mass (kg) | Time (days) | Dose/day (mL) | Total (mL) | Total bottles | Estimated cost (US$) |
| Gestational stage |
| Mare (pregnant) | 600 | 120 | 12 | 1,440 | 6.10 | $427.12 |
| Mare (lactating) | 550 | 180 | 11 | 1,980 | 8.39 | $587.29 |
| Mare total | | | | 14.49 | | $1,014.41 |
| Age of foal |
| Foal (0–3 months) | 50 | 90 | 1 | 90 | 0.38 | $26.69 |
| Foal (3–6 months) | 150 | 90 | 3 | 270 | 1.14 | $80.08 |
| Weanling (0.5–1 year) | 300 | 180 | 6 | 1,080 | 4.58 | $320.34 |
| Yearling (1–1.5 years) | 400 | 180 | 8 | 1,440 | 6.10 | $427.12 |
| Yearling (1.5–2 years) | 450 | 180 | 9 | 1,620 | 6.86 | $480.51 |
| 2–3 years | 500 | 360 | 10 | 3,600 | 15.25 | $1,067.80 |
| Foal total | | | | 34.32 | | $2,402.54 |
| Grand total | | | | 3,416.95 | | |

Notes: In order to prevent the development of eNAD/EDM in genetically susceptible foals, the mare and foal must be supplemented with 10 IU/kg/d of water soluble natural D-α-tocopherol (RRR-α-tocopherol) for an extended period of time. Estimated cost calculated using a 236 mL bottle of liquid natural vitamin E at a dose of 500 IU/mL at a cost of $70 a bottle.

Abbreviations: eNAD/EDM, equine neuroaxonal dystrophy/equine degenerative myeloencephalopathy.
adequate pasture is not available, the best practices outlined in Figure 1 should be followed.

Based on neonatal development studies at UC Davis, and previous research, clinical signs may be observable as early as 1–2 months of age. To provide the best treatment, foals should have a neurologic exam at 1 and 6 months of age, and every 6 months thereafter until 2 years of age for early disease detection (Figure 1). Within the first 4 months of life, the serum \( \alpha \)-tocopherol level of the foal should be assessed. Ideally, the serum \( \alpha \)-tocopherol level should be evaluated within the first week of life, as the difference between the 2 groups has been shown to be the largest during this time.

Serum \( \alpha \)-tocopherol concentrations of the dam can also be an indicator of the need for supplementation during pregnancy and lactation. Supplementation is indicated when serum concentrations are below 2 \( \mu \)g/mL in a pregnant mare. If eNAD/EDM is suspected in the foal, the dam and offspring should be supplemented at 10 IU/kg/d of \( \alpha \)-tocopherol (RRR-\( \alpha \)-tocopherol). Supplementation in the dam should begin at the start of the third trimester and end when the foal is weaned. The foal should be supplemented from birth to 3 years of age (Figure 1).

Current work is under way to develop an antemortem genetic test for eNAD/EDM at UC Davis. A genetic test would allow breeders to make more informed decisions about their breeding and management practices, ie, not breeding susceptible individuals in a dry climate lacking adequate access to pasture. A test would also allow veterinarians to better diagnose the cause of clinically observed ataxia.

**Acknowledgment**

The authors thank Anna Dahlgren and Francesca Gianino for their contributions to the manuscript.

**Disclosure**

Support for CJF was provided by the National Institutes of Health (NIH) (1K01OD015134 and L40 TR001136). ENB was supported by USDA NIFA National Need Fellowship Award #20143842021796. The authors report no other conflicts of interest in this work.

**References**